Rxsight Ownership
| RXST Stock | USD 13.05 0.09 0.68% |
Shares in Circulation | First Issued 2020-03-31 | Previous Quarter 40.4 M | Current Value 40.5 M | Avarage Shares Outstanding 29.1 M | Quarterly Volatility 8 M |
Rxsight Stock Ownership Analysis
About 95.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.91. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Rxsight has Price/Earnings To Growth (PEG) ratio of 0.03. The entity recorded a loss per share of 0.66. The firm had not issued any dividends in recent years. RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses used in cataract surgery in the United States and internationally. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California. Rxsight operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 221 people. To find out more about Rxsight contact Ronald MD at 949 521 7830 or learn more at https://www.rxsight.com.Besides selling stocks to institutional investors, Rxsight also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Rxsight's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Rxsight's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Rxsight Quarterly Liabilities And Stockholders Equity |
|
About 6.0% of Rxsight are currently held by insiders. Unlike Rxsight's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Rxsight's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Rxsight's insider trades
Rxsight Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Rxsight is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Rxsight backward and forwards among themselves. Rxsight's institutional investor refers to the entity that pools money to purchase Rxsight's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Crédit Agricole S.a. | 2025-03-31 | 786.1 K | T. Rowe Price Investment Management,inc. | 2025-03-31 | 719.8 K | Deutsche Bank Ag | 2025-03-31 | 655.5 K | Parkman Healthcare Partners Llc | 2025-03-31 | 631.2 K | No Street Gp Lp | 2025-03-31 | 600 K | Voloridge Investment Management, Llc | 2025-03-31 | 525.9 K | Atika Capital Management Llc | 2025-03-31 | 512.8 K | Royal Bank Of Canada | 2025-03-31 | 477 K | Renaissance Technologies Corp | 2025-03-31 | 451.6 K | Ra Capital Management, Llc | 2025-03-31 | 3.7 M | Blackrock Inc | 2025-03-31 | 3.1 M |
Rxsight Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Rxsight insiders, such as employees or executives, is commonly permitted as long as it does not rely on Rxsight's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Rxsight insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Rxsight Outstanding Bonds
Rxsight issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Rxsight uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Rxsight bonds can be classified according to their maturity, which is the date when Rxsight has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Rxsight Stock Analysis
When running Rxsight's price analysis, check to measure Rxsight's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rxsight is operating at the current time. Most of Rxsight's value examination focuses on studying past and present price action to predict the probability of Rxsight's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rxsight's price. Additionally, you may evaluate how the addition of Rxsight to your portfolios can decrease your overall portfolio volatility.